What CorePath Laboratories does

CorePath Laboratories is a privately held, physician-owned cancer diagnostics laboratory headquartered in San Antonio, Texas, founded in 2009 by Dr. Aamir Ehsan. The company provides comprehensive pathology and hematopathology services under a CAP-accredited and CLIA-certified laboratory framework, with testing modalities spanning morphologic evaluation, immunohistochemistry, multicolor flow cytometry, cytogenetics, FISH, PCR, next-generation sequencing, and liquid biopsy. Its flagship methodology, the 20/20 CORE Evaluation, integrates these modalities into a single consolidated pathology report ordered by board-certified pathologists on a medically necessary basis. CorePath serves health systems, hospitals, pathology practices, individual hematologists and oncologists, and BioPharma clients across more than 20 U.S. states, with international collaboration through the Indus Hospital and Health Network. Technology partnerships with BD Biosciences (FACSLyric flow cytometry), Ventana/Roche (BenchMark ULTRA), and Illumina (NextSeq 550) underpin the instrumentation layer, while proprietary platforms LabVizor (cloud LIS with EMR/EHR integration) and CoreScope (digital pathology) provide the data and workflow layer. Companion sub-brands include FlowBoost (turnkey flow cytometry lab deployment in 90 days), TC/PC service models, the Bone Marrow Clinic for in-house procedures, and HemePath Hub for pathology education.

Name

CorePath Laboratories

Legal name

CorePath Laboratories

Website

https://corepath.us

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

CorePath Laboratories is a CAP-accredited, CLIA-certified cancer diagnostics reference laboratory founded in 2009 in San Antonio, Texas, delivering integrated pathology services including flow cytometry, NGS, FISH, IHC, and liquid biopsy to health systems, hospitals, hematologists, oncologists, and BioPharma clients across 20+ U.S. states.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics and Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Cancer diagnostics laboratory
• Hematopathology services
• Flow cytometry testing
• Next generation sequencing
• Bone marrow biopsy procedures

Headquarters

HQ city

San Antonio

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Clinical Laboratory Testing Services: Laboratory diagnostics testing services including hematopathology, flow cytometry, NGS, FISH, IHC, cytogenetics, and molecular genetics. Services provided to health systems, hospitals, pathology practices, and individual providers. Revenue generated through insurance billing and direct client payments.
2. Hospital-Based Pathology Services: On-site pathology staffing and services at hospital locations including frozen section coverage, clinical laboratory oversight, and quality management.
3. BioPharma Clinical Trial Services: Companion diagnostics, drug/biomarker development, tissue banking, clinical trials support, and R&D collaboration services for pharmaceutical and biotech companies.
4. Bone Marrow Procedure Services: Minimally invasive bone marrow procedures performed at CorePath's facility, including STAT and routine options, with integrated laboratory testing and reporting.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

CorePath Laboratories is a physician-owned, CAP-accredited and CLIA-certified cancer diagnostics reference laboratory specializing in hematopathology and integrated oncology testing. The company's core offering, the 20/20 CORE Evaluation, consolidates morphology, flow cytometry, FISH, cytogenetics, PCR, and NGS testing into a single integrated report ordered as medically necessary by board-certified pathologists. Services span multi-color flow cytometry, next generation sequencing with liquid biopsy, FISH, cytogenetics, PCR, IHC, anatomic pathology subspecialties (breast, GI, GU, dermatopathology, podiatric), bone marrow biopsy procedures, and hospital-based pathology staffing.

Product overview

CorePath Laboratories operates as a unified cancer diagnostics platform offering comprehensive pathology services through an integrated portfolio of diagnostic products and testing services. The core offering is the 20/20 CORE Evaluation, a consolidated diagnostic approach combining morphology, flow cytometry, FISH, cytogenetics, PCR, and NGS testing. Supporting this are specialized services including the Bone Marrow Clinic for in-house biopsy procedures, CoreScope Digital Pathology for remote viewing and consultation, and FlowBoost for turnkey flow cytometry lab setup. LabVizor serves as the cloud-based LIS platform enabling EMR/EHR integration and electronic requisitions. The BioPharma division provides companion diagnostics and clinical trial support services. The HemePath Hub Education Program offers free pathology training across five tracks. Testing services span hematopathology, anatomic pathology, and subspecialty areas including surgical, breast, GI, GU, dermatopathology, and podiatric pathology. Core diagnostic modalities include multi-color flow cytometry, next generation sequencing with liquid biopsy capabilities, FISH, cytogenetics, PCR, and immunohistochemistry/special stains. The company also offers TC/PC service delivery models providing flexible options for flow cytometry, IHC, and FISH testing.

Differentiator

Problem solved

Functional benefit

Brands

• CoreScope Digital Pathology: Digital pathology platform for streamlined operations and remote pathology services
• FlowBoost
• LabVizor
• HemePath Hub
• 20/20 CORE Evaluation
• TC/PC Services
• CORE Liquid Biopsy
• FlowBoost: Turnkey Flow Lab

Products and services

• 20/20 CORE Evaluation Comprehensive integrated pathology evaluation that combines morphology, flow cytometry, cytogenetics, FISH, PCR, and NGS testing ordered as medically necessary by board-certified pathologists, delivering results in a single consolidated integrated report for hematologic and solid tumor cancer diagnostics.
• Bone Marrow Clinic Minimally invasive bone marrow aspiration and biopsy procedures performed by interventional pathologists at CorePath's state-of-the-art San Antonio facility, with on-site immediate testing, STAT and routine options, and integrated diagnostic reporting. Patients are referred by hematologists/oncologists and other providers.
• CoreScope Digital Pathology Digital pathology platform enabling remote slide viewing, whole slide imaging, remote consultation, cloud-based image management, and integration with the LabVizor LIS for streamlined operations and reduced errors.
• LabVizor LIS Cloud-based laboratory information system (LIS) supporting pre-accessioning to reporting, customized integrated reports, EMR/EHR integration, and electronic requisition (eREQ) workflows for client practices.
• FlowBoost Turnkey Flow Lab Turnkey service enabling pathology practices to set up a fully operational flow cytometry lab in 90 days or less, with equipment selection and validation, hematopathologist oversight, installation, and reporting and billing assistance.
• Flow Cytometry Testing Multi-color flow cytometry providing rapid measurement of multiple cell characteristics through laser-based analysis, including immunophenotyping for leukemia and lymphoma typing and cell subset analysis for immunodeficiency diseases. STAT same-day testing available for critical cases.
• Next Generation Sequencing (NGS) Comprehensive DNA and RNA sequencing for solid tumors and hematopoietic malignancies with over 400 DNA genes for solid tumors, over 300 genes for hematology, and over 1600 NCCN Guideline-supported RNA genes. Turnaround time under 10 days.
• Liquid Biopsy Testing Non-invasive blood-based testing using cell-free DNA/RNA (cfDNA/cfRNA) for monitoring therapy response and detecting patient relapse, applicable to both hematologic and solid tumor malignancies. Pan-Tumor Liquid Biopsy sensitivity of greater than 0.1 percent.
• Fluorescence In Situ Hybridization (FISH) Fluorescent probe technique for detecting DNA changes on chromosomes including deletions, duplications, translocations, and inversions for hematopoietic neoplasm diagnosis and prognosis. PML/RARA FISH results available in 4-6 hours for urgent cases.
• Cytogenetics (Chromosome Analysis) Chromosome analysis using G-banding to produce karyotypes for detecting large DNA changes and chromosomal abnormalities in hematopoietic neoplasms and constitutional disorders.
• Polymerase Chain Reaction (PCR) DNA amplification technology enabling detection of very small amounts of pathogen or disease in blood, bone marrow, or tissue with sensitivity to identify changes in 1 in 100,000 cells.
• Immunohistochemistry/Special Stains Antigen/protein evaluation in tissue cells using antibody-antigen binding for cancer diagnosis, tumor classification, and site-of-origin determination in metastatic tumors. Performed on the Ventana BenchMark ULTRA platform.
• Hematopathology Services Comprehensive hematopathology diagnostics including full bone marrow procedures, morphology, flow cytometry, FISH, cytogenetics, PCR, and NGS under the supervision of board-certified hematopathologists.
• Anatomic Pathology Services Subspecialty anatomic pathology services covering surgical pathology, breast pathology, gastrointestinal pathology, urologic pathology, podiatric pathology, and dermatopathology, supported by ancillary testing modalities.
• BioPharma / Clinical Trials Services Comprehensive pharmaceutical testing services for BioPharma and biotech clients, including companion diagnostics, drug and biomarker development, tissue banking, clinical trial support, collaboration with CROs/SMOs, and new test/platform validation.
• Technical Component/Professional Component (TC/PC) Offerings Flexible service delivery for flow cytometry, immunohistochemistry, and FISH, providing TC-only, PC-only, or combined Technical Component/Professional Component offerings with rapid turnaround time and community-based pathology expertise.
• HemePath Hub Education Program Free pathology learning program offering five distinct training tracks for hematopathology fellows, residents, practicing pathologists, hematology-oncology fellows, and international trainees with hands-on experience.
• Bone Marrow Biopsy Training Program Bone marrow procedure training course for providers, including staff training, certification, supplies, and cadaver lab proficiency sessions conducted at CorePath's San Antonio facility.
• Acute Leukemia Panel Flow cytometry diagnostic panel for diagnosing and monitoring treatment and remission of acute leukemias, with 24-48 hour turnaround time.
• Lymphoma Panel Flow cytometry diagnostic panel for diagnosing and monitoring treatment and remission of lymphomas with less than 48 hour turnaround time.
• PNH Panel Flow cytometry diagnostic panel for diagnosing and monitoring Paroxysmal Nocturnal Hemoglobinuria therapy, including WBC and RBC clone size analysis.
• CLL Prognostic Panel Flow cytometry diagnostic panel using CD38 and ZAP-70 markers to assist in determining chronic lymphocytic leukemia prognosis.
• Hospital-Based Pathology Staffing On-site board-certified pathologist staffing at hospital locations, including frozen section coverage, clinical laboratory oversight, quality management, and tumor board participation for partner health systems and community hospitals.

Quantifiable outcome

• Turnaround time of less than 10 days for most NGS testing
• +5 more outcomes

Named customers19 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

13 partnerships are on record, tiered core, flagship and minor.

• BD BiosciencescoreTechnology or IntegrationEquipment partnership for BD FACSLyric Flow Cytometry System used in CorePath's laboratory operations. BD provides flow cytometry instrumentation for multi-color analysis capabilities.
• Ventana (Roche)coreTechnology or IntegrationVentana BenchMark ULTRA immunohistochemistry staining platform partnership for automated IHC and ISH slide staining. Core technology vendor for specimen processing.
• IlluminacoreTechnology or IntegrationNextSeq 550 sequencing platform used for next generation sequencing testing services. Enables DNA and RNA expression analysis for solid and hematopoietic malignancies.
• MD Anderson Cancer CenterflagshipStrategic or Co-development PartnerAcademic affiliation for clinical lab scientist training, medical student education, and resident/fellow rotations. High-prestige partnership in cancer diagnostics education.
• UT Health San AntonioflagshipStrategic or Co-development PartnerPrimary academic affiliation with hematopathology fellowship and residency programs. Faculty connections and training pipeline for pathology professionals.
• UT Southwestern Medical CentercoreStrategic or Co-development PartnerAcademic affiliation for medical education and training programs in pathology.
• Indus Hospital and Health NetworkcoreStrategic or Co-development PartnerInternational healthcare partnership for pathology services and education collaboration. Special recognition awarded by Indus Hospital.
• PfizercoreStrategic or Co-development PartnerBioPharma collaboration for clinical trials, companion diagnostics, and drug development support services.
• RochecoreStrategic or Co-development PartnerBioPharma partnership for companion diagnostics development and clinical trial laboratory services.
• ModernaminorStrategic or Co-development PartnerBiotech partnership for clinical diagnostics development and testing services.
• BioNTechminorStrategic or Co-development PartnerBiotechnology partnership for clinical trial support and diagnostic testing.
• CovancecoreChannel Partner/ Reseller/ DistributorContract Research Organization partnership for clinical trial laboratory services and drug development support.
• Worldwide Clinical TrialscoreChannel Partner/ Reseller/ DistributorCRO partnership for clinical trial support and laboratory testing services.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NeoGenomics: Specialty oncology reference laboratory offering comprehensive hematopathology, flow cytometry, FISH, NGS, and liquid biopsy services to community oncology practices, hospitals, and pharma. The closest direct competitor to CorePath in cancer diagnostics with overlapping test menus and customer segments.
• PathGroup: Physician-led anatomic and clinical pathology reference laboratory serving hospitals, health systems, and physician practices across the Southeast and beyond with subspecialty expertise in hematopathology and molecular oncology comparable to CorePath's offering.
• Inform Diagnostics (formerly Caris MPI/Clarient): Specialty pathology and molecular profiling lab focused on oncology diagnostics with NGS, IHC and comprehensive tumor profiling services — directly comparable to CorePath's molecular and hematopathology menu and pharma/biotech trial work.
• BioReference Laboratories: National full-service clinical and anatomic pathology reference laboratory offering oncology, hematology, molecular and esoteric testing with extensive health system and physician relationships — competes with CorePath for similar send-out and pharma business.

Broad incumbents

• ARUP Laboratories: Major academic medical center-affiliated reference laboratory offering a broad esoteric test menu including hematopathology, molecular oncology and flow cytometry — serves as a national reference alternative where CorePath offers esoteric oncology work.
• Mayo Clinic Laboratories: Large academic reference laboratory with comprehensive hematopathology, molecular and oncology testing, supported by Mayo Clinic brand — competes for high-complexity send-outs, second opinions and clinical trial work that CorePath also targets.
• Quest Diagnostics: Largest U.S. clinical laboratory with national logistics, broad payor coverage and an expanding specialty oncology and advanced diagnostics portfolio — a broad incumbent competing for hospital, health system and pharma business adjacent to CorePath's core.
• Labcorp (Laboratory Corporation of America): National clinical and anatomic pathology laboratory with substantial oncology, molecular and hematopathology testing capabilities and a large pharma services division — competes with CorePath in both clinical and BioPharma channels.
• CBLPath / Sonic Healthcare USA: Specialty anatomic pathology reference laboratory network (CBLPath) backed by Sonic Healthcare, focused on hematopathology, dermatopathology and molecular oncology — competes with CorePath for subspecialty send-outs and esoteric oncology testing.

Emerging players

• Strata Oncology: Molecular profiling company focused on tumor NGS and precision oncology for community oncology practices — an emerging player intersecting CorePath's molecular and liquid biopsy business with a different go-to-market emphasis on broad pan-tumor screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/corepath-laboratories
• Xx.com/corepath

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorePath Laboratories